169 related articles for article (PubMed ID: 27545496)
1. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H; McDonald S; Hayes P; Dillon JF; Allen S; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley A; Bramley P; Hutchinson SJ
J Hepatol; 2017 Jan; 66(1):19-27. PubMed ID: 27545496
[TBL] [Abstract][Full Text] [Related]
2. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
[TBL] [Abstract][Full Text] [Related]
3. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
4. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
Bruno S; Di Marco V; Iavarone M; Roffi L; Crosignani A; Calvaruso V; Aghemo A; Cabibbo G; Viganò M; Boccaccio V; Craxí A; Colombo M; Maisonneuve P
J Hepatol; 2016 Jun; 64(6):1217-23. PubMed ID: 27059129
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
Backus LI; Belperio PS; Shahoumian TA; Mole LA
Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
[TBL] [Abstract][Full Text] [Related]
8. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
10. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection.
Valerio H; Goldberg DJ; Lewsey J; Weir A; Allen S; Aspinall EJ; Barclay ST; Bramley P; Dillon JF; Fox R; Fraser A; Hayes PC; Innes H; Kennedy N; Mills PR; Stanley AJ; Hutchinson SJ
Drug Alcohol Depend; 2015 Sep; 154():125-31. PubMed ID: 26183402
[TBL] [Abstract][Full Text] [Related]
11. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
Simmons B; Saleem J; Heath K; Cooke GS; Hill A
Clin Infect Dis; 2015 Sep; 61(5):730-40. PubMed ID: 25987643
[TBL] [Abstract][Full Text] [Related]
13. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
Imazeki F; Yokosuka O; Fukai K; Saisho H
Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
[TBL] [Abstract][Full Text] [Related]
14. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
[TBL] [Abstract][Full Text] [Related]
15. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
[TBL] [Abstract][Full Text] [Related]
16. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
[TBL] [Abstract][Full Text] [Related]
17. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.
Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ
J Hepatol; 2011 May; 54(5):879-86. PubMed ID: 21145812
[TBL] [Abstract][Full Text] [Related]
18. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
[TBL] [Abstract][Full Text] [Related]
19. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
20. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
Jacobson IM; Lim JK; Fried MW
Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]